Considering the fact that natriuretic peptides have been reported to enhance adiponectin production in patients with heart failure and adiponectin has been demonstrated to exert beneficial effects on myocardial systolic function through an antioxidant mechanism and AMP-activated protein kinase (AMPK)-dependent production of vascular endothelial growth factor, elevation of adiponectin production from epicardial adipose tissue may represent a counterregulatory response to myocardial insufficiency [24–27]. Here, ADIPOQ is linked to heart failure.